Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.